HK1072896A1 - G-type peptides to ameliorate atherosclerosis - Google Patents

G-type peptides to ameliorate atherosclerosis

Info

Publication number
HK1072896A1
HK1072896A1 HK05105238.6A HK05105238A HK1072896A1 HK 1072896 A1 HK1072896 A1 HK 1072896A1 HK 05105238 A HK05105238 A HK 05105238A HK 1072896 A1 HK1072896 A1 HK 1072896A1
Authority
HK
Hong Kong
Prior art keywords
peptides
type peptides
ameliorate
atherosclerosis
ameliorate atherosclerosis
Prior art date
Application number
HK05105238.6A
Other languages
English (en)
Inventor
Alan M Fogelman
Mohamad Navab
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1072896A1 publication Critical patent/HK1072896A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
HK05105238.6A 2002-04-05 2005-06-23 G-type peptides to ameliorate atherosclerosis HK1072896A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/120,508 US6930085B2 (en) 2002-04-05 2002-04-05 G-type peptides to ameliorate atherosclerosis
PCT/US2003/009988 WO2003086326A2 (en) 2002-04-05 2003-04-01 G-type peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
HK1072896A1 true HK1072896A1 (en) 2005-09-16

Family

ID=28674643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105238.6A HK1072896A1 (en) 2002-04-05 2005-06-23 G-type peptides to ameliorate atherosclerosis

Country Status (9)

Country Link
US (2) US6930085B2 (ja)
EP (1) EP1496930B1 (ja)
JP (1) JP4361809B2 (ja)
CN (1) CN1658893B (ja)
AT (1) ATE516811T1 (ja)
AU (1) AU2003262142C1 (ja)
CA (1) CA2480217C (ja)
HK (1) HK1072896A1 (ja)
WO (1) WO2003086326A2 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
MXPA05005031A (es) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
EP1599173B1 (en) * 2002-11-13 2017-02-22 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
CA2776927C (en) * 2004-04-15 2014-08-12 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
JP2005318829A (ja) * 2004-05-07 2005-11-17 Shigeru Kinoshita 抗菌性ペプチド、該抗菌性ペプチドをコードするポリヌクレオチド、並びに該抗菌性ペプチドを含有する抗菌剤、抗菌性医薬、点眼薬及び眼感染症疾患検査薬
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20060173067A1 (en) * 2004-08-11 2006-08-03 The Regents Of The University Of California Small molecules for the treatment of atherosclerosis
EP1796708A4 (en) * 2004-09-02 2009-07-08 Cognosci Inc IMPROVED APO-E ANALOGS AND USE METHOD THEREFOR
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
EP1797123B1 (en) * 2004-10-08 2010-03-03 Université de Liège COMPLEMENTARY PEPTIDES FOR ß-AMYLOID 29-42 PEPTIDE
ATE469174T1 (de) * 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
AU2005314043A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
CA2600898C (en) * 2004-12-07 2016-08-23 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
EP2269623A1 (en) 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
CA2659655A1 (en) * 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2008094905A2 (en) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2195331T3 (da) 2007-08-28 2014-02-03 Uab Research Foundation Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
AU2008296444A1 (en) * 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
WO2009093246A2 (en) * 2008-01-22 2009-07-30 Compugen Ltd. Novel clusterin derived peptide
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
KR20110130397A (ko) * 2009-03-13 2011-12-05 후지 세유 가부시키가이샤 항아테롬성동맥경화 작용이 있는 디펩티드
AU2012301955A1 (en) 2011-08-29 2014-03-06 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
CN114518458A (zh) * 2011-09-30 2022-05-20 私募蛋白质体运营有限公司 心血管危险事件预测及其用途
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
WO2014074682A1 (en) 2012-11-07 2014-05-15 Somalogic, Inc. Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
EP3189069A4 (en) * 2014-07-31 2018-03-07 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP2017530356A (ja) 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
JP7233737B2 (ja) 2017-05-26 2023-03-07 ビラマティクス スンディリアン ブルハド ペプチドおよび抗ウイルス剤としてのその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3933850A1 (de) * 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
US5733879A (en) 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5733549A (en) 1992-08-14 1998-03-31 Shino-Test Corporation Peptides including amino acid sequences selected from lipoprotein (a) and apolipoprotein (a), antibodies recognizing these amino acid sequences, and methods of determination using these antibodies
US5358934A (en) * 1992-12-11 1994-10-25 The United States Of America As Represented By The Secretary Of Agriculture Materials and methods for control of pests
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
WO1997009048A1 (en) 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
CA2249459A1 (en) 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
IN185761B (ja) 1997-05-13 2001-04-28 Council Scient Ind Res
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO1999047566A1 (en) 1998-03-17 1999-09-23 The Uab Research Foundation Synthetic peptides that enhance ldl uptake
WO2000034469A1 (en) * 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
JP2003525883A (ja) * 2000-03-03 2003-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
JP2005536456A (ja) 2005-12-02
ATE516811T1 (de) 2011-08-15
WO2003086326A2 (en) 2003-10-23
CA2480217A1 (en) 2003-10-23
US6930085B2 (en) 2005-08-16
AU2003262142A1 (en) 2003-10-27
CN1658893A (zh) 2005-08-24
EP1496930A2 (en) 2005-01-19
EP1496930A4 (en) 2006-06-21
CA2480217C (en) 2013-06-25
CN1658893B (zh) 2011-04-06
US20060258839A1 (en) 2006-11-16
US7638494B2 (en) 2009-12-29
JP4361809B2 (ja) 2009-11-11
WO2003086326A3 (en) 2004-03-25
EP1496930B1 (en) 2011-07-20
AU2003262142C1 (en) 2009-08-13
US20030191057A1 (en) 2003-10-09
AU2003262142B2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
HK1072896A1 (en) G-type peptides to ameliorate atherosclerosis
WO2006034056A3 (en) G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
TNSN07396A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DK1318828T3 (da) Oralt administrerede peptider til bedring af aterosklerose
IL162943A0 (en) High chromium-nitrogen bearing castable alloy
DK1423936T3 (da) Meddelelsesrekonstruktion fra partiel detektering
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
AU9502401A (en) Developing applications online
AU2003247967A8 (en) Interactive electronic commerce and message interchange system
HK1151575A1 (zh) 電照明火焰模擬器
PT1551372T (pt) Subunidade de sequestração e composições e métodos relacionados
DE60029798D1 (de) Ring zur verformung des magens
NO20044898L (no) Nye etonogestrel estere
DE60335962D1 (de) Bildanzeigeeinheit des projektionstyp
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
DE60331541D1 (de) Gaserzeugende Zusammensetzung
IS7537A (is) Notkun á nýjum etónógestrel esterum.
AU2003256256A8 (en) Bridge terminal output unit
WO2002006478A3 (en) Extracellular matrix protein
TW200608982A (en) Oral formulations of paricalcitol
ES1045770Y (es) Aparato corrector mandibular.
SE0004686D0 (sv) Immediate display message
GB0215366D0 (en) Modified music stand
ZA200401291B (en) Increased replacement of fly ash in cement compositions.
GB0012146D0 (en) Internet address system

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180401